BOSTON, MA, January 19, 2009 – PAREXEL International Corporation (NASDAQ: PRXL) will release Second Quarter Fiscal Year 2009 financial results on Monday, January 26, 2009 after the close of the stock market. The announcement will be available on PAREXEL’s website at www.parexel.com and on the PR Newswire website at www.prnewswire.com.

PAREXEL will host a conference call and live webcast at 10:00 a.m. ET on Tuesday, January 27, 2009 to discuss the results. To access the webcast, visit PAREXEL’s website at www.parexel.com, and click on the Investor Relations menu. This webcast will continue to be accessible for one year following the live broadcast. To participate via telephone, dial (612) 332-0720 and ask to join PAREXEL’s Second Quarter Earnings Conference Call.

About the CompanyPAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has over 9,180 employees. For more information about PAREXEL International visit www.parexel.com.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.